Skip to main content

COVID-19

      RT @bella_mehta: The one time at #ACR20 that only one sceen is on! #LTF @FauciFan @RheumNow so much respect for Dr Fauci
      4 years ago
      The one time at #ACR20 that only one sceen is on! #LTF @FauciFan @RheumNow so much respect for Dr Fauci! https://t.co/jhvlc8Py7R
      RT @DrMiniDey: Tracking CRP in the hyper-acute phase of admission for #COVID19 predictive of progression to critical ill
      4 years ago
      Tracking CRP in the hyper-acute phase of admission for #COVID19 predictive of progression to critical illness- suggests trends of inflammatory biomarkers, not absolute admission values, may be most useful for triage & therapy. Abs#0626 #ACR20 @RheumNow https://t.co/E14y3e4ALi
      Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day one: Safety of Recombinant Zoster Vaccine (RZV) (Abstract 0452…
      Outcomes for Rheumatic Disease Patients with COVID-19: Dr Kathryn Dao

      Dr. Kathryn Dao discusses plenary abstract #0430 presented Friday at the ACR 2020 annual meeting.

      Dr. Janet Pope interviews A&R Editor Dr. Daniel Solomon

      Dr. Janet Pope interviews Arthritis & Rheumatology Editor Dr. Daniel Solomon about his role as editor, COVID-19 related submissions, and overall journal submissions

      RT @Janetbirdope: Consistent data that antimalarials did NOT decrease hospitalization for viral infections in the pre #C
      4 years ago
      Consistent data that antimalarials did NOT decrease hospitalization for viral infections in the pre #COVID19 era in US claims database in SLE &RA pts #0002 @RheumNow @CRASCRRheum #ACR20 #ACR2020 https://t.co/nZp5dOeHXB
      RT @Janetbirdope: #COVID19 outcomes in systematic autoimmune diseases N=716 Pop’n matched by age & sex other COVID
      4 years ago
      #COVID19 outcomes in systematic autoimmune diseases N=716 Pop’n matched by age & sex other COVID pts. Glass is half empty. More hospitalization, ICU, ventilation but death 5% v 4.3%. Abstr#430 #ACR20 @RheumNow @CRASCRRheum https://t.co/cqko0Igd8L
      RT @drdavidliew: Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
      C
      4 years ago
      Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors? Can we learn lessons about collaborative work from @rheum_covid? Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
      RT @ejdein1: Great talk by @rheumcat @rheum_covid on COVID-19 impact on rheumatology. Talk to pts re: what to do with r
      4 years ago
      Great talk by @rheumcat @rheum_covid on COVID-19 impact on rheumatology. Talk to pts re: what to do with rheum rx... they haven't read guidelines and may make their own changes! Prepare them for exposure/ifn! #ACR20 @Rheumnow 2F042 https://t.co/HkxbkYjEm3
      RT @KDAO2011: Another study on rheum pt outcomes w/#COVID19: similar outcomes as nonrheum pts. MGH/JHU/Brigham 143 rheum
      4 years ago
      Another study on rheum pt outcomes w/#COVID19: similar outcomes as nonrheum pts. MGH/JHU/Brigham 143 rheum vs 688 nonrheum. No⬆️risk in rheums after adjusting for race/smoking/comorbidities for: hospitalizations, mech ventil'n 3. ICU 4. death #ACR20 Abstr#L01 @RheumNow https://t.co/362UZUe5dg